Drug trial tests new hope for Hard-to-Treat skin and lung disease
NCT ID NCT04781543
Summary
This trial tested an investigational drug called HZN-825 in adults with a severe form of systemic sclerosis, a disease that causes skin thickening and can damage the lungs. About 300 participants received either the drug or a placebo for one year to see if it could improve lung function and reduce skin tightness. The study was designed to measure changes in breathing tests and skin scores, as well as overall health and quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital de La Santa Creu i Sant Pau
Barcelona, 08025, Spain
-
Institute for Treatment and Rehabilitation Niska Banja
Niška Banja, 708120, Serbia
-
Institute of Rheumatology - PPDS
Belgrade, 11000, Serbia
-
Military Medical Academy
Belgrade, 11000, Serbia
Conditions
Explore the condition pages connected to this study.